Literature DB >> 29464458

PFO closure for secondary stroke prevention: is the discussion closed?

Joseph J Shatzel1,2, Molly M Daughety3, Vinay Prasad3, Thomas G DeLoughery3.   

Abstract

Three previous reports of PFO closure for secondary stroke prevention failed to find any significant benefit. Recently however, three conflicting reports were published suggesting a benefit in select patients. Although we are enthusiastic for PFO closure in appropriate patients, caution is warranted in the extrapolation of this data and the application of this intervention to broader patient groups. Only small minorities of stroke patients are likely to benefit from PFO closure, the intervention has a notable complication rate, and it has not been compared against modern anticoagulation options. Clinicians should consider all of these points as discussions around PFO closure are likely to become more and more common going forward.

Entities:  

Keywords:  Anticoagulation; PFO; PFO closure; Stroke

Mesh:

Year:  2018        PMID: 29464458     DOI: 10.1007/s11239-018-1633-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  13 in total

1.  Device Closure Versus Medical Therapy Alone for Patent Foramen Ovale in Patients With Cryptogenic Stroke: A Systematic Review and Meta-analysis.

Authors:  Rahman Shah; Mannu Nayyar; Ion S Jovin; Abdul Rashid; Beatrix R Bondy; Tai-Hwang M Fan; Michael P Flaherty; Sunil V Rao
Journal:  Ann Intern Med       Date:  2018-01-09       Impact factor: 25.391

2.  Editorial Commentary: Closure of the patent foramen ovale viewed from a different angle.

Authors:  Bernhard Meier; Fabian Nietlispach
Journal:  Trends Cardiovasc Med       Date:  2017-07-11       Impact factor: 6.677

3.  Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts.

Authors:  P T Hagen; D G Scholz; W D Edwards
Journal:  Mayo Clin Proc       Date:  1984-01       Impact factor: 7.616

4.  Closure or medical therapy for cryptogenic stroke with patent foramen ovale.

Authors:  Anthony J Furlan; Mark Reisman; Joseph Massaro; Laura Mauri; Harold Adams; Gregory W Albers; Robert Felberg; Howard Herrmann; Saibal Kar; Michael Landzberg; Albert Raizner; Lawrence Wechsler
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

5.  Apixaban in patients with atrial fibrillation.

Authors:  Stuart J Connolly; John Eikelboom; Campbell Joyner; Hans-Christoph Diener; Robert Hart; Sergey Golitsyn; Greg Flaker; Alvaro Avezum; Stefan H Hohnloser; Rafael Diaz; Mario Talajic; Jun Zhu; Prem Pais; Andrzej Budaj; Alexander Parkhomenko; Petr Jansky; Patrick Commerford; Ru San Tan; Kui-Hian Sim; Basil S Lewis; Walter Van Mieghem; Gregory Y H Lip; Jae Hyung Kim; Fernando Lanas-Zanetti; Antonio Gonzalez-Hermosillo; Antonio L Dans; Muhammad Munawar; Martin O'Donnell; John Lawrence; Gayle Lewis; Rizwan Afzal; Salim Yusuf
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.

Authors:  Lars Søndergaard; Scott E Kasner; John F Rhodes; Grethe Andersen; Helle K Iversen; Jens E Nielsen-Kudsk; Magnus Settergren; Christina Sjöstrand; Risto O Roine; David Hildick-Smith; J David Spence; Lars Thomassen
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

7.  Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.

Authors:  Jean-Louis Mas; Geneviève Derumeaux; Benoît Guillon; Evelyne Massardier; Hassan Hosseini; Laura Mechtouff; Caroline Arquizan; Yannick Béjot; Fabrice Vuillier; Olivier Detante; Céline Guidoux; Sandrine Canaple; Claudia Vaduva; Nelly Dequatre-Ponchelle; Igor Sibon; Pierre Garnier; Anna Ferrier; Serge Timsit; Emmanuelle Robinet-Borgomano; Denis Sablot; Jean-Christophe Lacour; Mathieu Zuber; Pascal Favrole; Jean-François Pinel; Marion Apoil; Peggy Reiner; Catherine Lefebvre; Patrice Guérin; Christophe Piot; Roland Rossi; Jean-Luc Dubois-Randé; Jean-Christophe Eicher; Nicolas Meneveau; Jean-René Lusson; Bernard Bertrand; Jean-Marc Schleich; François Godart; Jean-Benoit Thambo; Laurent Leborgne; Patrik Michel; Luc Pierard; Guillaume Turc; Martine Barthelet; Anaïs Charles-Nelson; Christian Weimar; Thierry Moulin; Jean-Michel Juliard; Gilles Chatellier
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

8.  Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.

Authors:  Jeffrey L Saver; John D Carroll; David E Thaler; Richard W Smalling; Lee A MacDonald; David S Marks; David L Tirschwell
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

9.  Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.

Authors:  John D Carroll; Jeffrey L Saver; David E Thaler; Richard W Smalling; Scott Berry; Lee A MacDonald; David S Marks; David L Tirschwell
Journal:  N Engl J Med       Date:  2013-03-21       Impact factor: 91.245

10.  Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study.

Authors:  Linxin Li; Gabriel S Yiin; Olivia C Geraghty; Ursula G Schulz; Wilhelm Kuker; Ziyah Mehta; Peter M Rothwell
Journal:  Lancet Neurol       Date:  2015-07-27       Impact factor: 59.935

View more
  1 in total

Review 1.  Stroke and presence of patent foramen ovale in sickle cell disease.

Authors:  Constantina Aggeli; Kali Polytarchou; Yannis Dimitroglou; Dimitrios Patsourakos; Sophia Delicou; Sophia Vassilopoulou; Eleftherios Tsiamis; Kostas Tsioufis
Journal:  J Thromb Thrombolysis       Date:  2021-02-26       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.